Inherited mutations in the BRCA1 gene confer increased susceptibility to breast and ovarian cancer. Its role in sporadic carcinogenesis is not well de®ned. Somatic mutations in breast cancers have not been reported and to date there are only three reports of somatic mutations in sporadic ovarian cancers. To investigate the contribution of BRCA1 mutations to sporadic breast and ovarian cancer in the Chinese population, we analysed 62 samples from Chinese women using the protein truncation test. There were 40 cases of breast cancer under age 50 and 22 cases of ovarian cancer, all unselected for family history. There was no age selection for the ovarian cancers. We found two somatic BRCA1 mutations in exon 11, one in a breast cancer and the other in an ovarian cancer, both of which result in truncated proteins. Our results indicate that somatic BRCA1 mutations, like somatic mutations in the BRCA2 gene, though very rare, can be found in both breast and ovarian cancers and support a tumor suppressor function for BRCA1 in sporadic tumors.
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The observed high incidence of loss of heterozygosity in the BRCA1 region in breast and ovarian tumors suggested the presence of somatic mutations in this gene. After the BRCA1 gene was cloned, Futreal et al. (1994) actively attempted to demonstrate this but failed to ®nd any somatic mutations in the 36 breast and 12 ovarian carcinomas they studied which showed LOH at the BRCA1 locus. The ®rst evidence for somatic BRCA1 mutations came from Merajver et al. (1995) , who described such mutations in four of their 47 ovarian cases studied. A further somatic mutation in an ovarian cancer was described by Hosking et al. (1995) and a few more have been reported recently by Berchuck et al. (1998) . No somatic BRCA1 mutation has ever been reported from breast cancer.
Molecular studies of BRCA1 mutations have generally been focused on Caucasian high-risk families (Szabo and King, 1997) . The Japanese are the only Asian population in the literature so far. Both Katagiri et al. (1996) and Matsushima et al. (1996) have reported a lower incidence of 3.8 and 5% in their breast and ovarian cancer population respectively. To investigate the contribution of BRCA1 mutations in the Chinese population of Hong Kong, we analysed a series of 40 breast and 22 ovarian cancer tumor samples from Chinese women, all cases being unselected for family history.
Sixty-two rapidly frozen fresh tumor specimens were obtained from mastectomy or excision specimens of patients treated for breast carcinoma in Queen Mary Hospital, Tung Wah and Pamela Youde Nethersole Hospitals, Hong Kong; and from excision specimens of patients with ovarian carcinoma in Queen Mary Hospital. Breast cancer cases diagnosed under the age of 50 were selected for this study. Fifteen of the breast cancer patients were between ages 41 ± 50, whereas the remaining 13 and 12 were between the ages 21 ± 35 and 36 ± 40, respectively. There was no age selection for the ovarian cancers which had ages ranging from 25 ± 77 years. The genomic DNA and total RNA were extracted using standard procedures. Non-tumor tissue was also collected whenever available. Informed consent in accord with ethical guidelines was obtained from individuals donating blood specimens for analysis. Prior to extraction, a histological section was cut from all blocks to con®rm the identity of tissues analysed.
The entire BRCA1 coding sequence was analysed using the protein truncation test as described previously (Ozcelik et al., 1996) . Fresh frozen tumor DNA samples showing truncated products on PTT, as well as DNA extracted from additional tumor and non-tumour samples of these cases were analysed by direct sequencing using Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham Life Sciences) as described by the manufacturer.
Mutations resulting in truncated protein products were identi®ed in exon 11 of BRCA1 in two cases (Figure 1) . Case 36 was a grade III in®ltrating ductal breast carcinoma, of no special histological type. The patient was aged 38 years, was lymph node negative, and the estrogen and progesterone receptor status of the carcinoma was negative. Case 18 was a poorly dierentiated serous papillary adenocarcinoma of the ovary from a patient aged 66 years. Both patients were con®rmed not to have any family history of breast or ovarian cancer. Forward and reverse sequence analysis revealed the 2893insA and C3145A mutations, in the breast and ovarian samples respectively (Table 1) . Interestingly, the sequencing analysis of non-tumor and peripheral blood samples from the same individuals showed the absence of mutation in the germline, indicating that these are somatic mutations. In order to con®rm this, as well as to exclude the possibility of sample mixing, DNA samples were further extracted from tumor and non-tumor sections of dierent tissue blocks from the same patients and re-analysed by sequencing. The tumor samples showed the presence of mutations, which were not found in the non-tumor samples. Moreover both forward and reverse sequence analysis of the tumor samples of both cases showed the presence of both mutant as well as wild type sequence. The presence of this wild type sequence in the tumor samples would most probably have been derived from non-malignant stroma included in the sections of both tumors. This was con®rmed by pathological evaluation of the histological sections taken from the tumor blocks used for DNA extraction.
To con®rm that the tumor and non-tumor samples of each case were derived from the same patient, tumor and non-tumor samples of both cases were also analysed with six dierent highly polymorphic microsattelite markers on chromosomes 7, 11 and 17. Markers with high frequency of heterozygosity were chosen (67 ± 90%) and it was thus expected that each individual would show a dierent pattern. DNA extracted from peripheral blood or tissue was subjected to PCR analysis in a 9600 Perkin Elmer Thermal Cycler using primers for six highly polymorphic di-and tetra-nucleotide repeat sequences (Research Genetics, Huntsville, AL, USA). Primer Sequencing of independent PCR products from tumor and non-tumor, done in both directions, revealed somatic mutations in BRCA1 for both cases; C3145A in case 18 and 289insA mutation in case 36. The partial DNA sequence of the coding strand of tumor and normal samples as illustrated, show the presence of both mutant and wild type DNA in the tumor samples. The normal DNA found in the tumor samples would have been derived from the non-malignant stroma included in the sections of ovarian and breast cancer loci (chromosomal location), expected length and heterozygosity rate were as follows: D7S522 (7q31), 217 ± 229 bp, 67%; D11S1294 (11q22-23), 294 bp, 83%; D11S2000 (11q22-23), 213 bp, 87%; D11S1818 (11q22-23), 142 ± 158 bp, 70%; D17S513 (17p13), 183 ± 203, 89%; TP53 (17p13), 103 ± 135 bp, 90%. The results shown in Figure 2 , indicate that within each individual both tumor and non-tumor samples share the same pattern of alleles. This evidence strengthens the assertion that tumor and non-tumor are from the same individual in each case.
To our knowledge this is the ®rst report of BRCA1 mutations in Chinese breast and ovarian cancer. In both cases, the absence of mutation in non-tumor tissue re¯ects the somatic nature of these mutations. The presence of the normal band in the PTT gel is most probably due to the invariable presence of some non-tumor DNA included in the DNA extracted from the tumor. Histological analysis of the sections taken from tumor blocks used for DNA extraction showed up approximately 30 ± 50% stromal tissue entrapped within the tumor tissue. Unfortunately, exclusion of these non-tumor components from the tumor sections could not be further minimized without the application of the technique of micro-dissection. Loss of heterozygosity was shown by Berchuck et al. (1998) to accompany both germline and somatic BRCA1 mutations in sporadic ovarian tumors.
Here we report the ®rst somatic mutation to be found in a sporadic breast cancer and the fourth report of somatic mutations in sporadic ovarian cancer. Both mutations we found are in exon 11, and give rise to abnormal truncated protein products. The reported low incidence of somatic BRCA1 mutations could be related partly to the fact that very few studies have focused on the mutational analysis of BRCA1 in sporadic tumors (Futreal et al., 1994; Merajver et al., 1995; Hosking et al., 1995; Matsushima et al., 1996; Takahashi et al., 1995; Berchuck et al., 1998) . Most studies of BRCA1 mutation have been directed at ®nding the mutations responsible for cases of familial breast cancer and have used peripheral blood samples.
The ®nding of novel somatic BRCA1 mutations in 4.6% (1/22) of ovarian and 2.5% (1/40) of young breast cancers in Chinese women supports the hypothesis that BRCA1 may play a role in the development of sporadic breast and ovarian cancers. Like that observed for somatic mutations in the BRCA2 gene (Foster et al., 1996; Lancaster et al., 1996; Miki et al., 1996; Weber et al., 1996) , somatic BRCA1 mutations, though very rare, can thus be also found in both breast and ovarian cancers. These ®ndings support a tumor suppressor function for BRCA1 in sporadic tumors. It also suggests that it may be valid to study alternative mechanisms of BRCA1 perturbations in sporadic tumors, including changes leading to low levels of expression of BRCA1 (Thompson et al., 1995; Ozcelik et al., 1998; Rice et al., 1998) . Table 2 for location of primer pairs and size of PCR products) 
